<p>argenx（纳斯达克：ARGX - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
<ul>
<li>3 家医疗行业的突破性公司，长期受益</li>
</ul>
<p>其他几家研究公司也对 ARGX 发表了看法。Piper Sandler 将 argenx 的目标股价从 820.00 美元上调至 930.00 美元，并在 11 月 4 日的研究报告中给予该股票 “超配” 评级。Wedbush 在 1 月 14 日的报告中重申了 “跑赢大盘” 评级，并设定了 1000.00 美元的目标股价。HC Wainwright 在 10 月 31 日的研究报告中将 argenx 的目标股价从 774.00 美元上调至 915.00 美元，并给予该公司 “买入” 评级。Wolfe Research 在 11 月 24 日的研究报告中重申了对 argenx 的 “同业表现” 评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 argenx 的 “持有（c）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，十八位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 986.78 美元。</p>
<p><strong>查看我们对 ARGX 的最新分析</strong></p>
<h2>argenx 股价下跌 1.1%</h2>
<ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
<p>纳斯达克：ARGX 周五开盘价为 811.45 美元。argenx 的 1 年最低价为 510.05 美元，1 年最高价为 934.62 美元。该公司的 50 日简单移动平均线为 844.08 美元，200 日简单移动平均线为 792.16 美元。该股票的市值为 502.1 亿美元，市盈率为 34.84，市盈增长比率为 0.70，贝塔值为 0.37。</p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者和对冲基金最近增加或减少了在 ARGX 的持股。Abound Wealth Management 在第四季度将其在 argenx 的持股增加了 3200.0%。Abound Wealth Management 现在拥有该公司 33 股股票，价值 28,000 美元，此前在上个季度又购买了 32 股。Sound Income Strategies LLC 在第四季度购买了 argenx 的新头寸，价值约 28,000 美元。Ameriflex Group Inc.在第三季度获得了 argenx 的新股份，价值约 32,000 美元。Sunbelt Securities Inc.在第三季度购买了 argenx 的新股份，价值约 36,000 美元。最后，Aventura Private Wealth LLC 在第四季度购买了 argenx 的新股份，价值约 38,000 美元。60.32% 的股票由机构投资者和对冲基金持有。</p>
<h2>argenx 公司简介</h2>
<p>（获取免费报告）</p>
<ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
<p>argenx（纳斯达克：ARGX）是一家生物技术公司，专注于针对严重自身免疫和神经肌肉疾病的抗体基础治疗的发现、开发和商业化。该公司利用其专有的 SIMPLE 抗体平台生成差异化的抗体和工程化的 Fc 区域，并追求调节新生 Fc 受体（FcRn）以降低致病性 IgG 水平的机制。Argenx 的研发活动涵盖靶点识别、临床前开发和旨在满足免疫学未满足需求的后期临床项目。</p>
<p>该公司的主打产品 efgartigimod（市场名称为 Vyvgart）是一种 FcRn 拮抗剂，旨在减少循环的 IgG 抗体并治疗 IgG 介导的疾病。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票比 argenx 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>6.5 亿美元对人工智能未来的押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
<p>在你考虑投资 argenx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
<p>虽然 argenx 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 ETF - SPDR

ARGX

动态生物技术与基因组 ETF - Invesco

基因改革 ETF - ARK

IBBQ

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>华尔街禅将 argenex（NASDAQ:ARGX）的评级从 “买入” 下调至 “持有”。其他公司对此持有不同看法，Piper Sandler 将其目标价上调至 930 美元，并维持 “增持” 评级，而 Wedbush 则设定了 1000 美元的目标价，并给予 “跑赢大盘” 评级。该股票的共识评级为 “适度买入”，平均目标价为 986.78 美元。目前，argenex 的交易价格为 811.45 美元，市值为 502.1 亿美元，市盈率为 34.84。机构投资者持有该股票的 60.32%</p>

<p>argenex (NASDAQ:ARGX - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Sunday.</p>
<div class="lb-trans"><p>argenx（纳斯达克：ARGX - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 的股票研究分析师将评级从 “买入” 下调至 “持有”。</p>
</div><ul>
<li>3 Healthcare Pathbreakers With Long-Term Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>3 家医疗行业的突破性公司，长期受益</li>
</ul>
</div><p>Several other research firms have also weighed in on ARGX. Piper Sandler boosted their price objective on shares of argenex from $820.00 to $930.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, November 4th. Wedbush reiterated an &#34;outperform&#34; rating and set a $1,000.00 price target on shares of argenex in a report on Wednesday, January 14th. HC Wainwright upped their price objective on argenex from $774.00 to $915.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wolfe Research reaffirmed a &#34;peer perform&#34; rating on shares of argenex in a research report on Monday, November 24th. Finally, Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of argenex in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $986.78.</p>
<div class="lb-trans"><p>其他几家研究公司也对 ARGX 发表了看法。Piper Sandler 将 argenx 的目标股价从 820.00 美元上调至 930.00 美元，并在 11 月 4 日的研究报告中给予该股票 “超配” 评级。Wedbush 在 1 月 14 日的报告中重申了 “跑赢大盘” 评级，并设定了 1000.00 美元的目标股价。HC Wainwright 在 10 月 31 日的研究报告中将 argenx 的目标股价从 774.00 美元上调至 915.00 美元，并给予该公司 “买入” 评级。Wolfe Research 在 11 月 24 日的研究报告中重申了对 argenx 的 “同业表现” 评级。最后，Weiss Ratings 在 1 月 21 日的研究报告中重申了对 argenx 的 “持有（c）” 评级。一位投资分析师给予该股票 “强烈买入” 评级，十八位分析师给予 “买入” 评级，四位分析师给予 “持有” 评级，一位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，该公司目前的共识评级为 “适度买入”，平均目标价格为 986.78 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ARGX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ARGX 的最新分析</strong></p>
</div><h2>argenex Trading Down 1.1%</h2>
<div class="lb-trans"><h2>argenx 股价下跌 1.1%</h2>
</div><ul>
<li>5 medical stocks growing earnings by triple digits</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只医疗股票的收益增长达到三位数</li>
</ul>
</div><p>NASDAQ:ARGX opened at $811.45 on Friday. argenex has a 1-year low of $510.05 and a 1-year high of $934.62. The firm has a fifty day simple moving average of $844.08 and a 200 day simple moving average of $792.16. The stock has a market capitalization of $50.21 billion, a PE ratio of 34.84, a P/E/G ratio of 0.70 and a beta of 0.37.</p>
<div class="lb-trans"><p>纳斯达克：ARGX 周五开盘价为 811.45 美元。argenx 的 1 年最低价为 510.05 美元，1 年最高价为 934.62 美元。该公司的 50 日简单移动平均线为 844.08 美元，200 日简单移动平均线为 792.16 美元。该股票的市值为 502.1 亿美元，市盈率为 34.84，市盈增长比率为 0.70，贝塔值为 0.37。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARGX. Abound Wealth Management lifted its holdings in shares of argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company's stock worth $28,000 after buying an additional 32 shares in the last quarter. Sound Income Strategies LLC bought a new position in argenex during the fourth quarter worth about $28,000. Ameriflex Group Inc. acquired a new stake in argenex in the 3rd quarter worth about $32,000. Sunbelt Securities Inc. bought a new stake in argenex in the 3rd quarter valued at about $36,000. Finally, Aventura Private Wealth LLC bought a new stake in argenex in the 4th quarter valued at about $38,000. 60.32% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近增加或减少了在 ARGX 的持股。Abound Wealth Management 在第四季度将其在 argenx 的持股增加了 3200.0%。Abound Wealth Management 现在拥有该公司 33 股股票，价值 28,000 美元，此前在上个季度又购买了 32 股。Sound Income Strategies LLC 在第四季度购买了 argenx 的新头寸，价值约 28,000 美元。Ameriflex Group Inc.在第三季度获得了 argenx 的新股份，价值约 32,000 美元。Sunbelt Securities Inc.在第三季度购买了 argenx 的新股份，价值约 36,000 美元。最后，Aventura Private Wealth LLC 在第四季度购买了 argenx 的新股份，价值约 38,000 美元。60.32% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>argenex Company Profile</h2>
<div class="lb-trans"><h2>argenx 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><ul>
<li>Argenx's 28% Surge &amp; Promising Product Propel Investor Confidence</li>
</ul>
<div class="lb-trans"><ul>
<li>Argenx 的 28% 激增和有前景的产品提升了投资者信心</li>
</ul>
</div><p>argenx NASDAQ: ARGX is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx's research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.</p>
<div class="lb-trans"><p>argenx（纳斯达克：ARGX）是一家生物技术公司，专注于针对严重自身免疫和神经肌肉疾病的抗体基础治疗的发现、开发和商业化。该公司利用其专有的 SIMPLE 抗体平台生成差异化的抗体和工程化的 Fc 区域，并追求调节新生 Fc 受体（FcRn）以降低致病性 IgG 水平的机制。Argenx 的研发活动涵盖靶点识别、临床前开发和旨在满足免疫学未满足需求的后期临床项目。</p>
</div><p>The company's lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.</p>
<div class="lb-trans"><p>该公司的主打产品 efgartigimod（市场名称为 Vyvgart）是一种 FcRn 拮抗剂，旨在减少循环的 IgG 抗体并治疗 IgG 介导的疾病。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than argenex</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票比 argenx 更好</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>6.5 亿美元对人工智能未来的押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJHWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ARGX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in argenex Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 argenx 吗？</h2>
</div><p>Before you consider argenex, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 argenx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 argenx 并不在名单上。</p>
</div><p>While argenex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 argenx 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Argenx (NASDAQ:ARGX) 被华尔街 Zen 下调评级至 “持有”